[go: up one dir, main page]

CL2011002675A1 - Uso de compuestos derivados de nitrato o sulfato de 9-purin-9-il-3,4-dihidroxitetrahidrofuran-2-il-metilo para reducir la presion intraocular ; composicion farmaceutica oftalmica que comprende los compuestos; y formulacion oftalmica de uso topico que los comprende. - Google Patents

Uso de compuestos derivados de nitrato o sulfato de 9-purin-9-il-3,4-dihidroxitetrahidrofuran-2-il-metilo para reducir la presion intraocular ; composicion farmaceutica oftalmica que comprende los compuestos; y formulacion oftalmica de uso topico que los comprende.

Info

Publication number
CL2011002675A1
CL2011002675A1 CL2011002675A CL2011002675A CL2011002675A1 CL 2011002675 A1 CL2011002675 A1 CL 2011002675A1 CL 2011002675 A CL2011002675 A CL 2011002675A CL 2011002675 A CL2011002675 A CL 2011002675A CL 2011002675 A1 CL2011002675 A1 CL 2011002675A1
Authority
CL
Chile
Prior art keywords
compounds
ophthalmic
dihydroxytetrahydrofuran
purin
pharmaceutical composition
Prior art date
Application number
CL2011002675A
Other languages
English (en)
Inventor
Shikha Baumgarter Rodulf A Barman
Original Assignee
Inotek Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43030847&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2011002675(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Inotek Pharmaceuticals Corp filed Critical Inotek Pharmaceuticals Corp
Publication of CL2011002675A1 publication Critical patent/CL2011002675A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Prostheses (AREA)

Abstract

Método para reducir la presión intraocular en seres humanos; composición farmacéutica oftálmica que comprende compuestos derivados de nitrato o sulfato de 9-purin-9-il-3,4-dihidroxitetrahidrofuran-2-il-metilo; y formulación oftálmica de uso tópico que los comprende.
CL2011002675A 2009-05-01 2011-10-27 Uso de compuestos derivados de nitrato o sulfato de 9-purin-9-il-3,4-dihidroxitetrahidrofuran-2-il-metilo para reducir la presion intraocular ; composicion farmaceutica oftalmica que comprende los compuestos; y formulacion oftalmica de uso topico que los comprende. CL2011002675A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17465509P 2009-05-01 2009-05-01
US21999009P 2009-06-24 2009-06-24

Publications (1)

Publication Number Publication Date
CL2011002675A1 true CL2011002675A1 (es) 2012-06-01

Family

ID=43030847

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2011002675A CL2011002675A1 (es) 2009-05-01 2011-10-27 Uso de compuestos derivados de nitrato o sulfato de 9-purin-9-il-3,4-dihidroxitetrahidrofuran-2-il-metilo para reducir la presion intraocular ; composicion farmaceutica oftalmica que comprende los compuestos; y formulacion oftalmica de uso topico que los comprende.

Country Status (25)

Country Link
US (2) US8470800B2 (es)
EP (1) EP2424546B1 (es)
JP (1) JP5778663B2 (es)
KR (1) KR101757940B1 (es)
CN (1) CN102413832B (es)
AU (1) AU2010242943B2 (es)
BR (1) BRPI1009971A2 (es)
CA (1) CA2762064A1 (es)
CL (1) CL2011002675A1 (es)
DK (1) DK2424546T3 (es)
EA (1) EA024042B1 (es)
ES (1) ES2554684T3 (es)
HR (1) HRP20151200T1 (es)
HU (1) HUE028068T2 (es)
IL (1) IL216081A (es)
MX (1) MX2011011229A (es)
MY (1) MY159244A (es)
NZ (1) NZ596428A (es)
PL (1) PL2424546T3 (es)
PT (1) PT2424546E (es)
RS (1) RS54378B1 (es)
SG (1) SG175346A1 (es)
SI (1) SI2424546T1 (es)
SM (1) SMT201500295B (es)
WO (1) WO2010127210A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102008062567A1 (de) 2008-12-16 2010-06-17 Bayer Schering Pharma Aktiengesellschaft Dipeptoid-Prodrugs und ihre Verwendung
DE102009006602A1 (de) * 2009-01-29 2010-08-05 Bayer Schering Pharma Aktiengesellschaft Alkylamino-substituierte Dicyanopyridine und deren Aminosäureester-Prodrugs
MX2012004225A (es) * 2009-10-26 2012-06-08 Inotek Pharmaceuticals Corp Formulacion oftalmica y metodo de fabricacion de la misma.
ME02608B (me) 2010-01-11 2017-06-20 Inotek Pharmaceuticals Corp Kombinacija, komplet i postupak snižavanja intraokularnog pritiska
WO2011116292A1 (en) * 2010-03-19 2011-09-22 Inotek Pharmaceuticals Corporation Combination compositions of adenosine a1 agonists and non-selective beta-adrenergic receptor blockers for reducing intraocular pressure
ES2613254T3 (es) * 2010-03-19 2017-05-23 Inotek Pharmaceuticals Corporation Composiciones de combinación de agonistas de adenosina A1 e inhibidores de anhidrasa carbónica para reducir la presión intraocular
PH12012501906A1 (en) * 2010-03-26 2013-01-14 Inotek Pharmaceuticals Corp Method of reducing intraocular pressure in humans using n6 -cyclopentyladenosine (cpa), cpa derivatives or prodrugs thereof
DE102010030688A1 (de) 2010-06-30 2012-01-05 Bayer Schering Pharma Aktiengesellschaft Substituierte Dicyanopyridine und ihre Verwendung
US20120058983A1 (en) 2010-09-02 2012-03-08 Bayer Pharma Aktiengesellschaft Adenosine A1 agonists for the treatment of glaucoma and ocular hypertension
DK2807178T3 (en) * 2012-01-26 2017-09-04 Inotek Pharmaceuticals Corp Anhydrous polymorphs of (2R, 3S, 4R, 5R) -5- (6- (cyclopentylamino) -9H-purin-9-yl) -3,4-dihydroxytetrahydrofuran-2-yl) methyl nitrate and processes for their preparation
HK1214951A1 (zh) 2013-03-15 2016-08-12 Inotek Pharmaceuticals Corporation 眼用製劑
EA201790851A1 (ru) * 2014-12-03 2017-11-30 Инотек Фармасьютикалз Корпорейшн Способы предотвращения, уменьшения и лечения макулодистрофии

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2343421T3 (es) * 2004-05-26 2010-07-30 Inotek Pharmaceuticals Corporation Derivados de purina como agonistas de los receptores a1 de adenosina y metodos de uso de los mismos.
CN101010085B (zh) * 2004-05-26 2012-12-26 伊诺泰克制药公司 嘌呤衍生物作为腺苷a1受体激动剂及其用法
NZ568392A (en) * 2005-11-30 2011-07-29 Inotek Pharmaceuticals Corp Purine derivatives and methods of use thereof
MX2012004225A (es) * 2009-10-26 2012-06-08 Inotek Pharmaceuticals Corp Formulacion oftalmica y metodo de fabricacion de la misma.
ME02608B (me) * 2010-01-11 2017-06-20 Inotek Pharmaceuticals Corp Kombinacija, komplet i postupak snižavanja intraokularnog pritiska
WO2011116292A1 (en) * 2010-03-19 2011-09-22 Inotek Pharmaceuticals Corporation Combination compositions of adenosine a1 agonists and non-selective beta-adrenergic receptor blockers for reducing intraocular pressure
ES2613254T3 (es) * 2010-03-19 2017-05-23 Inotek Pharmaceuticals Corporation Composiciones de combinación de agonistas de adenosina A1 e inhibidores de anhidrasa carbónica para reducir la presión intraocular

Also Published As

Publication number Publication date
EP2424546B1 (en) 2015-10-28
ES2554684T3 (es) 2015-12-22
SI2424546T1 (sl) 2016-02-29
SG175346A1 (en) 2011-11-28
KR20120017026A (ko) 2012-02-27
HRP20151200T1 (hr) 2016-01-15
IL216081A0 (en) 2012-01-31
RS54378B1 (en) 2016-04-28
AU2010242943B2 (en) 2016-09-29
EP2424546A4 (en) 2013-01-23
PL2424546T3 (pl) 2016-04-29
MX2011011229A (es) 2011-11-18
KR101757940B1 (ko) 2017-07-13
HUE028068T2 (en) 2016-11-28
JP2012525437A (ja) 2012-10-22
JP5778663B2 (ja) 2015-09-16
EP2424546A1 (en) 2012-03-07
CA2762064A1 (en) 2010-11-04
CN102413832B (zh) 2015-11-25
US20100279970A1 (en) 2010-11-04
IL216081A (en) 2015-11-30
MY159244A (en) 2016-12-30
SMT201500295B (it) 2016-01-08
PT2424546E (pt) 2015-12-23
EA024042B1 (ru) 2016-08-31
US20130217643A1 (en) 2013-08-22
HK1167599A1 (en) 2012-12-07
EA201171339A1 (ru) 2012-05-30
WO2010127210A1 (en) 2010-11-04
DK2424546T3 (en) 2015-12-14
NZ596428A (en) 2014-03-28
US8470800B2 (en) 2013-06-25
CN102413832A (zh) 2012-04-11
BRPI1009971A2 (pt) 2016-03-15
AU2010242943A1 (en) 2011-12-01

Similar Documents

Publication Publication Date Title
CL2011002675A1 (es) Uso de compuestos derivados de nitrato o sulfato de 9-purin-9-il-3,4-dihidroxitetrahidrofuran-2-il-metilo para reducir la presion intraocular ; composicion farmaceutica oftalmica que comprende los compuestos; y formulacion oftalmica de uso topico que los comprende.
DOP2019000005A (es) 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostéricos de shp2
DOP2010000304A (es) Composiciones y metodos de preparacion y uso de las mismas
CR20130033A (es) Formulaciones de rifaximina y usos de las mismas
CL2012003281A1 (es) Uso de compuestos específicos estimuladores y/o activadores de sgc; formulacion farmaceutica que comprende dichos compuestos; kit que comprende los compuestos, y uso para la prevencion y/o tratamiento de la esclerosis sistematica.
CL2008002319A1 (es) Compuestos derivados de pirrolopirimidina; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer.
CL2015003801A1 (es) Formulaciones de anticuerpos y metodos
CL2009001484A1 (es) Sal glicinato de metformina; composición farmacéutica que comprende la sal; y su uso para tratar la hiperglicemia.
UY31673A1 (es) "derivados heterocíclicos de urea y métodos de uso de los mismos-211"
SV2010003559A (es) Algunos derivados de 2-pirazinona y su uso como inhibidores de elastasa de los neutrofilos
CR20160222U (es) Formas solidas de acido { [ -(3- clorofenil) -3- hidroxipiridin -2-carbonil] amino} acetico, composiciones, y usos de las mismas
MX353827B (es) Formas de rifaximina y usos de la misma.
CL2014001158A1 (es) Compuestos derivados de piperazina alquilados; composicion farmaceutica que los comprende; proceso para preparar la composicion farmaceutica; kit y uso en el tratamiento de trastornos inmunes, cancer, enfermedades cardiovasculares, inflamacion, entre otros.
AR047928A1 (es) Derivados de tetrahidropiridoindol
CL2012003075A1 (es) Composicion farmaceutica en solucion de pazopanib, estable y para uso oftalmico; metodo para la preparacion de dicha solucion.
GT201200321A (es) Derivados de heteroaril imidazolona como inhibidores de jak
BRPI1106572B8 (pt) Composições que compreendem um retinoide e um inibidor de nfkb e seus métodos de uso
CL2008002430A1 (es) Compuestos derivados de bencenosulfonamida, inhibidores de catepsina c; composicion farmaceutica que los comprende; y su uso para el tratamiento de la epoc.
CL2008001123A1 (es) Compuestos derivados de acido lipoico; formulacion farmaceutica que lo comprende; y uso en el tratamiento del cancer.
GT201000047A (es) Mejoras en compuestos organicos o relacionadas con los mismos
CL2008001323A1 (es) Compuestos derivados de triazolil aminopiridina; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer.
BR112015030356A2 (pt) métodos de tratamento de uma taupatia
UY35276A (es) Nuevos compuestos que inhiben la actividad de Lp-PLA2
UY34008A (es) ?formas en estado sólido de inhibidor de hiv, composición farmacéutica, uso de la misma, y procesos para preparar dichas formas?.
SV2018005760A (es) Derivados de aminotiazol utiles como agentes antiviricos